Dividend stocks can be a port in the storm. Thanks to powerful wealth-building vehicles like dividend reinvestment plans, these stocks can take advantage of the power of both dollar-cost averaging and compounding. However, not all dividend stocks are great buys. Companies with unusually high yields can be particularly risky for a variety of reasons.
Which high-yield dividend stocks stand out as top buys right now? Pharmaceutical giant Takeda Pharmaceutical(NYSE: TAK) and telecom stalwart AT&T(NYSE: T) both screen as attractive buys at current levels. Read on to find out more about these two elite dividend stocks.
Takeda Pharmaceutical: A 4.4% annualized dividend yield
Takeda Pharmaceutical is a global leader in the pharmaceutical industry, with a diversified portfolio of drugs and vaccines. The company has a strong presence in Japan, the U.S., Europe, and emerging markets. Takeda focuses on four therapeutic areas: oncology, rare diseases, neuroscience, and gastroenterology. The company also has a robust pipeline of experimental drugs and vaccines, with over 50 candidates in ongoing clinical trials.
Takeda pays a generous dividend of 4.4%, which is well above the average of 2.3% for the healthcare sector. The company has a payout ratio of approximately 49%, indicating it should have ample room to grow its payout in the years to come. Underscoring this point, most big pharma stocks sport payout ratios well north of 50%. Takeda's dividend is supported by an overall improving financial picture. Over the past five years, for instance, the Japanese pharma giant has grown its annual revenue by 18.4%, earnings per share by 15.8%, and free cash flow by 45.5%.
At under 10 times projected earnings, Takeda stock is substantially undervalued compared to its peers. Large-cap pharma stocks, after all, trade at an average earnings multiple of 15.1. Takeda's low valuation reflects a handful of important risks, such as key patent headwinds for top-selling drugs like Vyvanse, along with the company's highly leveraged balance sheet. However, these risks aren't insurmountable and Takeda has done an admirable job of positioning the company for long-term growth. All told, Takeda stock may be worth buying for its attractive valuation, robust pipeline, and above-average dividend yield.
AT&T: A 7.9% annualized yield
AT&T is one of the largest telecommunications companies in the world, with over 222 million wireless subscribers and over 15 million broadband customers. At present, the telecom giant offers shareholders an eye-popping 7.9% annualized yield. However, this sizable yield has largely been the byproduct of AT&T's falling share price. In 2023, the company's shares have plunged by nearly 23% over concerns about its free-cash-flow generation in the back half of the year, potential liability over legacy infrastructure, a high debt load, limited growth prospects, as well as the emergence of low-cost competitors.
On the bright side, this double-digit drop in AT&T's shares has put them firmly in bargain territory. The stock trades at a forward price-to-earnings ratio of 5.8, which is well below the industry average of 12.7. AT&T stock, in turn, has probably bottomed out, making it a great bargain income play at current levels.
That being said, there's the remote risk the telecom company may be on the hook for a large sum stemming from its exposure to antiquated lead-covered cables. AT&T, for its part, has repeatedly downplayed this risk factor, citing the company's continuous efforts to safeguard the public from hazards associated with this ancient infrastructure.
Bottom line: This high-yield telecom stock should be able to deliver outstanding returns over the next five to 10 years, despite this infrastructure overhang.
10 stocks we like better than Takeda Pharmaceutical
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now... and Takeda Pharmaceutical wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 21, 2023
George Budwell has positions in AT&T. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
